Major histocompatibility complex class i and ii expression in idiopathic inflammatory myopathy

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 6, 2013, Pages 539-542

  Das, Leena ^a   Blumbergs, Peter C ^b   Manavis, Jim ^b   Limaye, Vidya S ^c,d  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b HANSON INSTITUTE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Idiopathic inflammatory myopathy; Immunostaining; Major histocompatibility complex class I and II expression

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE CLASSIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE TISSUE; POLYMYOSITIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

BIOLOGICAL MARKERS; BIOPSY; DERMATOMYOSITIS; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE, SKELETAL; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 84892433146     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31827d7f16     Document Type: Article

References (30)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;13:344-347.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;20:403-407.
3. Bohan A, Peter JB, Bowman RL, et al. Computer- A ssisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56:255-286.
4. Hohlfeld R. Polymyositis and dermatomyositis. In: Karpati G, ed. Structural and Molecular Basis of Skeletal Muscle Diseases. Switzerland: ISN Neuropath Press; 2002:221-227.
5. Hewer E, Goebel HH. Myopathology of non-infectious inflammatory myopathies. The current status. Pathol Res Pract. 2008; 204:609-623.
6. Dalakas MC. Inflammatory muscle diseases: A critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:1-7.
7. Nagaraju K. Update on immunopathogenesis in inflammatory myopathies. Curr Opin Rheumatol. 2001;13:461-468.
8. Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med. 1991;325:1487-1498.
9. Matsubara S, Hirai S, Sawa Y. Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol. 1997;76:75-80.
10. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-982.
11. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today. 1994;15:269-274.
12. Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol. 1998;113:407-414.
13. Tajima Y, Moriwaka F, Tashiro K. Temporal alterations of immunohistochemical findings in polymyositis. Intern Med. 1994; 33:263-270.
14. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fibre damage and dysfunction. Arthritis Rheum. 2005;52:1824-1835.
15. Civatte M, Schleinitz N, Krammer P, et al. Class I MHC detection as a diagnostic tool in non informative muscle biopsies of patients suffering from dermatomyositis. Neuropathol Appl Neurobiol. 2003;29:546-552.
16. Daar AS, Fiigglc SV, Fabrc JW, et al. The detailed distribution of MHC class II in normal human organs. Transplantation. 1984; 38:293-298.
17. Cifuentes-Diaz C, Delaporte C, Dautreaux B, et al. Class II MHC antigens in normal human skeletal muscle. Muscle Nerve. 1992;3: 295-302.
18. Goebels N, Michaclis D, Wekerle H, et al. Human myoblasts as antigen-presenting cells. J Immunol. 1992;149:661-667.
19. Rowe D, Iseiiberg DA, Beverlcy PCL. Monoclonal anlibodies to immune leukocyte antigens in polymyositis and muscular dystrophy. Clin Exp Immunol. 1983;54:327-336.
20. Olsson T, Henrlksson KG, Klarcskog L, et al. HLA-DR expression T lymphocyte phenotypes, OK Ml and OKT) reactive cells in inflammatory myopalhy. Muscle Nerve. 1985;8:419-425.
21. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988;23:64-72.
22. McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci. 1989;89:213-226.
23. Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40:e237-e247.
24. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70: 418-424.
25. Mastaglia FL, Philips VA. Idiopathic inflammatory myopathies, epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am. 2002;28:723-741.
26. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of b- A myloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol. 1992;141:31-36.
27. Jain A, Sharma MC, Sarkar C, et al. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch Pathol Lab Med. 2007;131: 1070-1076.
28. Sundaram C, Uppin MS, Meena AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India. 2008;56:363-367.
29. Van der Pas J, Hengstman GJ, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2004;75:136-139.
30. Salaroli R, Baldin E, Papa V, et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. J Clin Pathol. 2012;65:14-19.